In clinical trials, the dose range of BCMA-targeted CAR-T cells for the treatment of relapsed/refractory multiple myeloma mostly covered the range from 0.5 × 106 cells/kg (NCT03672253) to 5 × 106 cells/kg (NCT04194931) (Fig. 2A). This evidence concerns the gene TNFRSF17 and plasma cell myeloma.